Developer docs
API playgroundTry for free, no card

Search company profiles

Phosphorex

Full company profile

uuid00074gy

Namestring
Phosphorex
Legal namestring
Phosphorex LLC
Websiteurl
phosphorex.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Phosphorex serves biotech and biopharmaceutical customers developing nucleic acid medicines (mRNA, siRNA, pDNA), gene and RNA therapies, vaccines, oncology therapeutics, and long-acting injectables that require specialized formulation, analytical, and CMC support. Revenue is generated through project-based, custom-quoted CDMO contracts spanning feasibility through preclinical development, with active investment in cGMP manufacturing capacity intended to extend the offering into clinical-stage production. The company is backed by Ampersand Capital Partners as primary financial sponsor and by NOF Corporation as a strategic minority shareholder and technology partner. Go-to-market is enterprise-direct, relying on industry conference presence (ASGCT, BIO International, LNP Formulation & Process Development Summit), educational webinars, technical content, and the LNP Alliance ecosystem to reach R&D and CMC decision-makers at client biotech and pharma organizations.

Short descriptiontext

Phosphorex is a private Hopkinton, Massachusetts-based CDMO specializing in lipid nanoparticles, polymeric nanoparticles, and polymeric microspheres for advanced therapeutic delivery to biotech and pharma clients developing nucleic acid, gene, vaccine, and sustained-release drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHopkinton, United States
HQ citystring
Hopkinton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery systems, lipid nanoparticle formulation, CDMO services, polymeric nanoparticles, sustained release microspheres
Industry3 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Phosphorex generates revenue as a CDMO providing drug delivery formulation, process development, analytical services, and tech transfer support to biotech and pharma companies developing advanced therapeutics. Services span from early feasibility through clinical translation, with revenue generated through project-based contracts and potentially recurring engagement as programs advance through development phases.

phosphorex.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Phosphorex is a contract development and manufacturing organization (CDMO) providing drug delivery formulation, process development, analytical services, and tech transfer for advanced therapeutics. Its core offerings are built around three particle-based drug delivery platforms — lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres — combined within the integrated Phosphorex Drug Delivery Engine that advances programs from early feasibility through preclinical development and GMP manufacturing readiness.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Phosphorex is a drug delivery-focused CDMO offering an integrated platform of particle-based drug delivery solutions organized around the Phosphorex Drug Delivery Engine. The core platform encompasses three main drug delivery technologies: Lipid Nanoparticles (LNPs), Polymeric Nanoparticles (PNPs), and Polymeric Microspheres, each addressing different therapeutic delivery needs from nucleic acid delivery to sustained-release applications. The Drug Delivery Engine itself consists of four interconnected modules: Formulation Optimization, Process Design & CMC, Analytical Expertise, and Tech Transfer/Process Optimization. These are complemented by Licensable LNP Development Services (as NOF Corporation's North American LNP Center of Excellence) and the LNP Alliance partnership for integrated end-to-end development. The company supports diverse therapeutic modalities including nucleic acid delivery, gene and RNA medicines, vaccines, oncology, and long-acting injectables.

Product and service6 records
1Phosphorex Drug Delivery Engine
CategoryDrug Delivery Development Platform
Description

Integrated drug delivery development platform that combines formulation optimization, process design and CMC, analytical expertise, and tech transfer capabilities to advance nanoparticle-based therapeutics from concept to clinic. Available to biotech and pharma clients as the overarching CDMO engagement.

2Lipid Nanoparticles (LNPs)
CategoryDrug Delivery Platform
Description

Next-generation lipid nanoparticle platform CDMO offering for delivering nucleic acids to extra-hepatic tissues with cell-specific targeting capabilities. Serves biotech and pharma developers of mRNA, siRNA, pDNA, gene editing, and vaccine programs.

3Polymeric Nanoparticles (PNPs)
CategoryDrug Delivery Platform
Description

Biodegradable polymer-based nanoparticle CDMO offering using polyethylene glycol (PEG) copolymers for precise targeting and payload protection from degradation. Available to developers needing targeted delivery of nucleic acids, peptides, proteins, and small molecules.

4Polymeric Microspheres
CategoryDrug Delivery Platform
Description

Sustained-release microsphere CDMO offering using biodegradable polymers for encapsulating small molecules, peptides, and proteins to prolong drug exposure and reduce dosing frequency. Supports long-acting injectable and sustained-release therapeutic programs.

5Licensable LNP Development Services
CategoryLNP Development Services
Description

Center-of-excellence offering providing evaluation of LNP candidates from NOF Corporation's proprietary, licensable ionizable lipid libraries with high-throughput screening, candidate nomination, and in vivo validation. Designed for biotech and pharma clients seeking licensable LNP technology.

6LNP Alliance
CategoryPartnership Platform
Description

Strategic partnership platform offering an integrated end-to-end lipid nanoparticle development offering combining proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1LNP Alliance (NeoSome Life Sciences, NanoImaging Services, Envol Biomedical)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

The LNP Alliance brings together Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical to provide an integrated, end-to-end platform for lipid nanoparticle development. The alliance combines proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic. Each member contributes specialized expertise across the LNP development lifecycle.

phosphorex.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Innovative preclinical CRO providing comprehensive in vitro and in vivo services to support drug discovery and development across various therapeutic areas. Member of the LNP Alliance providing biodistribution, efficacy, and toxicology evaluations in multiple animal models including Non-Human Primates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Leader in cryo-electron microscopy (cryo-EM) and nanoparticle characterization, ensuring the highest quality and integrity for LNP-based therapeutics. Provides Cryo-TEM imaging for nanoparticle characterization as part of the LNP Alliance ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Leading non-clinical laboratory offering pharmacology and toxicology capabilities focused on Non-Human Primates. Member of the LNP Alliance providing in vivo efficacy and safety evaluation services.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-30
Description

Collaboration to supply Phosphorex's global clients with NOF's COATSOME SS Series proprietary ionizable lipids. The combination of NOF's lipid technologies and Phosphorex's experience in developing and scaling LNP-based drug delivery solutions delivers faster, more cost-effective, and reproducible outcomes for customers. This integrated approach provides a well-characterized platform for customers developing LNP-based therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioVectra (acquired by Agilent) is a CDMO specializing in complex small molecules, biologics, and nucleic acid manufacturing including plasmid DNA and LNP components; it serves a comparable biotech CDMO customer base for advanced therapeutics.

TypeBroad incumbent
Description

Lonza is a leading global CDMO with significant nucleic acid, LNP, and biologics manufacturing capacity; its Mammalian, Microbial, and mRNA services compete with Phosphorex for advanced therapeutics development contracts at the upper end of the market.

TypeDirect peer
Description

Genevant is an LNP delivery technology company that licenses lipid nanoparticle platforms and provides formulation services to nucleic acid developers; it directly overlaps with Phosphorex's LNP formulation and licensing business model.

TypeDirect peer
Description

Precision NanoSystems, acquired by Cytiva/Danaher in 2023, is a direct competitor offering LNP formulation instruments (NanoAssemblr), lipids, and CDMO services for nucleic acid delivery — directly competing with Phosphorex's LNP-focused CDMO offering for biotech and pharma clients.

TypeDirect peer
Description

Aldevron (acquired by Danaher) is a CDMO providing nucleic acids, proteins, and mRNA manufacturing services to gene therapy and vaccine developers; it overlaps with Phosphorex on the nucleic acid therapeutic development customer base.

TypeDirect peer
Description

Ascendia Pharma is a specialty CDMO focused on pre-formulation, formulation, and nano-emulsion/nanoparticle drug delivery for poorly soluble drugs and complex injectables, providing comparable nano-formulation CDMO services to biotech clients.

TypeDirect peer
Description

TriLink (a Maravai LifeSciences company) manufactures mRNA, oligonucleotides, and nucleic acids for therapeutic and vaccine developers; it serves the same biotech customer base as Phosphorex and offers adjacent CDMO services in nucleic acid-based therapeutics.

TypeBroad incumbent
Description

CordenPharma is a full-service CDMO with growing lipid nanoparticle and nucleic acid manufacturing capabilities (including via the Moderna alliance); it competes broadly with Phosphorex for nucleic acid CDMO contracts from larger pharma and biotech clients.

9Evonik Health Care
TypeBroad incumbent
Description

Evonik offers lipid excipients, polymeric microspheres (RESOMER), and CDMO services for parenteral and complex injectable formulations; its RESOMER polymer and lipid portfolio competes directly with Phosphorex's polymeric microsphere and LNP offerings.

TypeDirect peer
Description

Acuitas is an LNP technology specialist whose ionizable lipids underpin Pfizer-BioNTech's Comirnaty vaccine; it develops LNP formulations for partners and is a direct competitor in the nucleic acid delivery CDMO and licensing space where Phosphorex operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phosphorex

Pharmaceutical Contract Development and Manufacturing (CDMO)phosphorex.com

Phosphorex is a private Hopkinton, Massachusetts-based CDMO specializing in lipid nanoparticles, polymeric nanoparticles, and polymeric microspheres for advanced therapeutic delivery to biotech and pharma clients developing nucleic acid, gene, vaccine, and sustained-release drugs.

What Phosphorex does

Phosphorex serves biotech and biopharmaceutical customers developing nucleic acid medicines (mRNA, siRNA, pDNA), gene and RNA therapies, vaccines, oncology therapeutics, and long-acting injectables that require specialized formulation, analytical, and CMC support. Revenue is generated through project-based, custom-quoted CDMO contracts spanning feasibility through preclinical development, with active investment in cGMP manufacturing capacity intended to extend the offering into clinical-stage production. The company is backed by Ampersand Capital Partners as primary financial sponsor and by NOF Corporation as a strategic minority shareholder and technology partner. Go-to-market is enterprise-direct, relying on industry conference presence (ASGCT, BIO International, LNP Formulation & Process Development Summit), educational webinars, technical content, and the LNP Alliance ecosystem to reach R&D and CMC decision-makers at client biotech and pharma organizations.

Phosphorex firmographics

Firmographics
Name
Phosphorex
Legal name
Phosphorex LLC
Website
https://phosphorex.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Phosphorex is a private Hopkinton, Massachusetts-based CDMO specializing in lipid nanoparticles, polymeric nanoparticles, and polymeric microspheres for advanced therapeutic delivery to biotech and pharma clients developing nucleic acid, gene, vaccine, and sustained-release drugs.
Ownership category
akta.pro rank

Phosphorex industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Drug delivery systems
  • Lipid nanoparticle formulation
  • CDMO services
  • Polymeric nanoparticles
  • Sustained release microspheres

Where Phosphorex is headquartered

Location

Headquarters

HQ city
Hopkinton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Phosphorex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Phosphorex generates revenue as a CDMO providing drug delivery formulation, process development, analytical services, and tech transfer support to biotech and pharma companies developing advanced therapeutics. Services span from early feasibility through clinical translation, with revenue generated through project-based contracts and potentially recurring engagement as programs advance through development phases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Phosphorex product offering

Product offering

Core offering

Phosphorex is a contract development and manufacturing organization (CDMO) providing drug delivery formulation, process development, analytical services, and tech transfer for advanced therapeutics. Its core offerings are built around three particle-based drug delivery platforms — lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres — combined within the integrated Phosphorex Drug Delivery Engine that advances programs from early feasibility through preclinical development and GMP manufacturing readiness.

Product overview

Phosphorex is a drug delivery-focused CDMO offering an integrated platform of particle-based drug delivery solutions organized around the Phosphorex Drug Delivery Engine. The core platform encompasses three main drug delivery technologies: Lipid Nanoparticles (LNPs), Polymeric Nanoparticles (PNPs), and Polymeric Microspheres, each addressing different therapeutic delivery needs from nucleic acid delivery to sustained-release applications. The Drug Delivery Engine itself consists of four interconnected modules: Formulation Optimization, Process Design & CMC, Analytical Expertise, and Tech Transfer/Process Optimization. These are complemented by Licensable LNP Development Services (as NOF Corporation's North American LNP Center of Excellence) and the LNP Alliance partnership for integrated end-to-end development. The company supports diverse therapeutic modalities including nucleic acid delivery, gene and RNA medicines, vaccines, oncology, and long-acting injectables.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phosphorex Drug Delivery Engine Integrated drug delivery development platform that combines formulation optimization, process design and CMC, analytical expertise, and tech transfer capabilities to advance nanoparticle-based therapeutics from concept to clinic. Available to biotech and pharma clients as the overarching CDMO engagement.
  • Lipid Nanoparticles (LNPs) Next-generation lipid nanoparticle platform CDMO offering for delivering nucleic acids to extra-hepatic tissues with cell-specific targeting capabilities. Serves biotech and pharma developers of mRNA, siRNA, pDNA, gene editing, and vaccine programs.
  • Polymeric Nanoparticles (PNPs) Biodegradable polymer-based nanoparticle CDMO offering using polyethylene glycol (PEG) copolymers for precise targeting and payload protection from degradation. Available to developers needing targeted delivery of nucleic acids, peptides, proteins, and small molecules.
  • Polymeric Microspheres Sustained-release microsphere CDMO offering using biodegradable polymers for encapsulating small molecules, peptides, and proteins to prolong drug exposure and reduce dosing frequency. Supports long-acting injectable and sustained-release therapeutic programs.
  • Licensable LNP Development Services Center-of-excellence offering providing evaluation of LNP candidates from NOF Corporation's proprietary, licensable ionizable lipid libraries with high-throughput screening, candidate nomination, and in vivo validation. Designed for biotech and pharma clients seeking licensable LNP technology.
  • LNP Alliance Strategic partnership platform offering an integrated end-to-end lipid nanoparticle development offering combining proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic.

Companies that use Phosphorex

Customer profile

Segments1 record

Ideal customer profiles1 record

Phosphorex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Phosphorex partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • LNP Alliance (NeoSome Life Sciences, NanoImaging Services, Envol Biomedical)coreStrategic or Co-development Partner · 8 May 2025The LNP Alliance brings together Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical to provide an integrated, end-to-end platform for lipid nanoparticle development. The alliance combines proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic. Each member contributes specialized expertise across the LNP development lifecycle.
  • NeoSome Life SciencescoreStrategic or Co-development Partner · 8 May 2025Innovative preclinical CRO providing comprehensive in vitro and in vivo services to support drug discovery and development across various therapeutic areas. Member of the LNP Alliance providing biodistribution, efficacy, and toxicology evaluations in multiple animal models including Non-Human Primates.
  • NanoImaging ServicescoreStrategic or Co-development Partner · 8 May 2025Leader in cryo-electron microscopy (cryo-EM) and nanoparticle characterization, ensuring the highest quality and integrity for LNP-based therapeutics. Provides Cryo-TEM imaging for nanoparticle characterization as part of the LNP Alliance ecosystem.
  • Envol BiomedicalcoreStrategic or Co-development Partner · 8 May 2025Leading non-clinical laboratory offering pharmacology and toxicology capabilities focused on Non-Human Primates. Member of the LNP Alliance providing in vivo efficacy and safety evaluation services.
  • NOF AMERICA CORPORATIONcoreTechnology or Integration · 30 April 2024Collaboration to supply Phosphorex's global clients with NOF's COATSOME SS Series proprietary ionizable lipids. The combination of NOF's lipid technologies and Phosphorex's experience in developing and scaling LNP-based drug delivery solutions delivers faster, more cost-effective, and reproducible outcomes for customers. This integrated approach provides a well-characterized platform for customers developing LNP-based therapies.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Phosphorex competitors and assessment

Company assessment

Direct peers

  • BioVectra: BioVectra (acquired by Agilent) is a CDMO specializing in complex small molecules, biologics, and nucleic acid manufacturing including plasmid DNA and LNP components; it serves a comparable biotech CDMO customer base for advanced therapeutics.
  • Genevant Sciences: Genevant is an LNP delivery technology company that licenses lipid nanoparticle platforms and provides formulation services to nucleic acid developers; it directly overlaps with Phosphorex's LNP formulation and licensing business model.
  • Precision NanoSystems (Cytiva): Precision NanoSystems, acquired by Cytiva/Danaher in 2023, is a direct competitor offering LNP formulation instruments (NanoAssemblr), lipids, and CDMO services for nucleic acid delivery — directly competing with Phosphorex's LNP-focused CDMO offering for biotech and pharma clients.
  • Aldevron: Aldevron (acquired by Danaher) is a CDMO providing nucleic acids, proteins, and mRNA manufacturing services to gene therapy and vaccine developers; it overlaps with Phosphorex on the nucleic acid therapeutic development customer base.
  • Ascendia Pharma: Ascendia Pharma is a specialty CDMO focused on pre-formulation, formulation, and nano-emulsion/nanoparticle drug delivery for poorly soluble drugs and complex injectables, providing comparable nano-formulation CDMO services to biotech clients.
  • TriLink BioTechnologies: TriLink (a Maravai LifeSciences company) manufactures mRNA, oligonucleotides, and nucleic acids for therapeutic and vaccine developers; it serves the same biotech customer base as Phosphorex and offers adjacent CDMO services in nucleic acid-based therapeutics.
  • Acuitas Therapeutics: Acuitas is an LNP technology specialist whose ionizable lipids underpin Pfizer-BioNTech's Comirnaty vaccine; it develops LNP formulations for partners and is a direct competitor in the nucleic acid delivery CDMO and licensing space where Phosphorex operates.

Broad incumbents

  • Lonza: Lonza is a leading global CDMO with significant nucleic acid, LNP, and biologics manufacturing capacity; its Mammalian, Microbial, and mRNA services compete with Phosphorex for advanced therapeutics development contracts at the upper end of the market.
  • CordenPharma: CordenPharma is a full-service CDMO with growing lipid nanoparticle and nucleic acid manufacturing capabilities (including via the Moderna alliance); it competes broadly with Phosphorex for nucleic acid CDMO contracts from larger pharma and biotech clients.
  • Evonik Health Care: Evonik offers lipid excipients, polymeric microspheres (RESOMER), and CDMO services for parenteral and complex injectable formulations; its RESOMER polymer and lipid portfolio competes directly with Phosphorex's polymeric microsphere and LNP offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Phosphorex social profiles

Digital presence

Phosphorex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phosphorex leadership team

Management profile

Number of profiles

Profiles12 records

Phosphorex funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phosphorex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phosphorex

What does Phosphorex do?

Phosphorex is a contract development and manufacturing organization (CDMO) providing drug delivery formulation, process development, analytical services, and tech transfer for advanced therapeutics. Its core offerings are built around three particle-based drug delivery platforms — lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres — combined within the integrated Phosphorex Drug Delivery Engine that advances programs from early feasibility through preclinical development and GMP manufacturing readiness.

Is Phosphorex a public or private company?

Phosphorex is a private company. It is classified as private equity controlled and is currently operating.

When was Phosphorex founded?

Phosphorex was founded in 2005. It employs 11 to 50 people.

Where is Phosphorex based?

Phosphorex is headquartered in Hopkinton, United States, in the North America region.

How does Phosphorex make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Phosphorex's main competitors?

Direct peers on record are BioVectra, Genevant Sciences, Precision NanoSystems (Cytiva), Aldevron, Ascendia Pharma, TriLink BioTechnologies and Acuitas Therapeutics. Broad incumbents are Lonza, CordenPharma and Evonik Health Care.

Does Phosphorex have an API?

No public API is recorded for Phosphorex.

What industry is Phosphorex in?

Phosphorex's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePhosphorex to Host a Virtual Panel Discussion Exploring Targeted Lipid Nanoparticle Development for Extrahepatic DeliveryPhosphorex is hosting a free, one-hour virtual panel discussion on July 29, 2026, along with fellow LNP Alliance members NOF Corporation and NeoSome Life Sciences, focused on targeted lipid nanoparticle development for extrahepatic delivery. The discussion will bring together four scientists to address practical approaches including iterative formulation optimization, quality attributes assessment, and strategies like covalent conjugation and post-insertion methods for ligand incorporation. The session aims to provide a practical framework for advancing ligand-conjugated LNPs from formulation through preclinical validation.citybizPhosphorex Elevates John Rigg to Chairman as Demand Grows for Advanced Drug Delivery ExpertisePhosphorex has appointed pharmaceutical manufacturing veteran John Rigg as chairman of its board of directors, reinforcing its leadership as demand grows for specialized drug delivery technologies including lipid nanoparticles, polymeric nanoparticles and long-acting injectable systems. Rigg brings over two decades of leadership experience including executive roles at Eli Lilly, Ventria Bioscience, Sigma-Tau Pharmaceuticals and most recently CEO positions at Exelead Biopharma and NanoImaging Services. The appointment signals Phosphorex's strategy to scale its position in the pharmaceutical services market as biologics, nucleic acid therapies and precision medicines drive increasing demand for specialized drug delivery expertise.PR NewswirePhosphorex Names John Rigg Chairman of the BoardPhosphorex, a drug delivery-focused contract development and manufacturing organization (CDMO) specializing in lipid nanoparticles and polymeric delivery platforms, has appointed John Rigg as Chairman of its Board of Directors. Rigg brings over 20 years of pharmaceutical and biomanufacturing leadership experience, having previously served as CEO of NanoImaging Services and Exelead Biopharma, and held senior roles at Eli Lilly & Company. The appointment comes as demand for specialized drug delivery expertise grows amid increasing advancement of nucleic acid medicines and targeted therapies toward clinical development.BioSpacePhosphorex Names John Rigg Chairman of the BoardPhosphorex named John Rigg chairman of its board, a role he joined in 2024. Rigg brings decades of leadership experience from Eli Lilly, Ventria Bioscience, and other pharma companies. The appointment comes as the company expands its drug delivery capabilities.PR NewswirePhosphorex Appoints Jerry Williamson as Chief Executive OfficerPhosphorex, a drug delivery-focused contract development and manufacturing organization (CDMO) and Ampersand Capital Partners portfolio company, has appointed Jerry Williamson as Chief Executive Officer effective August 13, 2025. Williamson brings over 35 years of leadership experience in bioscience and diagnostics, having previously served as CEO of Sengenics and held executive roles at NanoView Biosciences, KEW, Inc., and Metamark Genetics. The appointment is positioned as a strategic move to accelerate Phosphorex's growth in lipid nanoparticle (LNP) formulation and cGMP manufacturing for RNA, gene, and small molecule therapeutics.PR NewswireJarlath Keating Joins as President of Solvias Group USA to Drive Growth and Innovation in Advanced Analytical ServicesSolvias, a global provider of CMC analytical services for the biopharmaceutical industry, announced the appointment of Jarlath Keating as President of Solvias Group USA to lead its U.S. expansion. Keating brings nearly 30 years of industry experience from senior roles at Phosphorex, LLC, Advanced Bioscience Laboratories, and BioReliance. Solvias has recently expanded its Research Triangle Park, North Carolina facility and achieved cGMP readiness to support biopharma clients from early-stage development through commercial release.PR NewswirePhosphorex Announces the Opening of their Innovation & Training Center, Showcasing Phosphorex's Lipid Nanoparticle (LNP) Development Capabilities Combined with NOF's Proprietary Ionizable Lipid, COATSPhosphorex, a drug delivery-focused contract development and manufacturing organization (CDMO), announced the opening of its Lipid Nanoparticle (LNP) Innovation & Training Center in Hopkinton, Massachusetts. The center combines Phosphorex's LNP fabrication services—including microfluidics, jet mixing, T-mixing, and Tangential Flow Filtration—with NOF Corporation's proprietary ionizable lipid library to help pharmaceutical clients optimize LNP formulations for their drug development projects. The partnership represents an expansion of the existing Phosphorex-NOF collaboration, providing customers with hands-on training, workshops, and access to screening capabilities for lipid-based drug delivery systems.YahooPhosphorex Welcomes NOF CORPORATION as Shareholder and Strategic PartnerNOF CORPORATION completed a strategic investment in Phosphorex, a drug delivery CDMO, making it a minority shareholder. The investment will accelerate Phosphorex's cGMP capability and strengthen collaboration, with NOF's COATSOME SS Series of ionizable lipids supporting its LNP-based drug delivery market position.PR NewswirePhosphorex Welcomes NOF CORPORATION as Shareholder and Strategic PartnerNOF CORPORATION completed a strategic investment in Phosphorex, becoming a minority shareholder and strategic partner. The funding will accelerate the establishment of Phosphorex's cGMP capabilities and strengthen their collaboration on nanoparticle-based drug delivery solutions. This partnership aims to advance Phosphorex's growth plans while consolidating NOF's position in the lipid nanoparticle market.PhosphorexPrecision Drug Delivery CDMONOF Corporation has completed a strategic investment in Phosphorex, becoming a minority shareholder in the drug delivery-focused CDMO. The funding is intended to accelerate Phosphorex's cGMP capabilities and strengthen its collaboration with NOF for nanoparticle-based drug delivery solutions. This partnership aims to advance novel therapeutics while consolidating NOF’s position in the lipid nanoparticle market.